Medidata Blog

Bring Your Own Device—the Future of eCOA Studies?

May 20, 2020

Traditionally, eCOA studies have provided hardware, whether tablets or handheld devices, for sites and patients to provide and enter data. With the exponential growth in availability of technology over the last decades there has been a growing interest in taking advantage of patients' own smartphone devices to allow them to access and complete study questionnaires.

Given Medidata's strong technology focus, we developed our eCOA solution to be application (“app”) based for flexibility and scalability, allowing us to deploy traditional provisioned studies, purely "Bring Your Own Device" (BYOD) studies, or some combination thereof, depending on the needs of a given trial. We have a solution that can be configured to create the best solution for a specific study, with all the data flowing through to the broader Medidata platform.

Currently, there is a lack of explicit regulatory guidance on the acceptability of data captured using BYOD in support of pivotal endpoints. While the FDA have signalled that they recognize BYOD as a natural evolution of the use of electronic modes of data capture in trials, they have also expressed some concerns. Firstly, patients should not be excluded from a clinical trial because they do not own what, at the end of the day, is an expensive piece of hardware. Realistically, some level of provisioning of devices in eCOA studies is going to be a reality for the foreseeable future, both to support patients without a suitable device or if patients simply do not want to use their own device.

Secondly, the FDA has suggested that the use of many different device-types in a single study would introduce an additional source of variability to the patient-reported data. While clinical trials are in a constant battle against reducing uncontrolled variability, significant research has been done over the last decades on the comparability of data captured on a range of different modalities and device types, which shows that patients answer consistently across modes of administration.

While there is updated industry guidance coming soon on the issue of comparability, until there is a clear statement from the regulators, it is recommended that the appropriateness of a BYOD methodology, and potential need for any additional testing, is discussed with regulators when formulating the COA strategy for a particular trial. This is particularly the case for Phase III studies when the data is supporting pivotal endpoints. There may be more flexibility in Phase II studies, or for exploratory endpoints, and indeed these may be good scenarios in which to demonstrate the suitability of the BYOD methodology in anticipation of future larger pivotal trials.

Medidata’s Rave Patient Cloud, particularly Rave eCOA’s app-based infrastructure, allows us to easily create a single build of a study, which can be deployed across provisioned or patients own devices, as the needs of the study dictate. This approach allows us to meet the stringent regulatory requirements of capturing key endpoint data in clinical trials, while also pushing and empowering the industry to adopt technological solutions with increasing insight into the patients’ experiences, amplifying their voice in trials, while decreasing the burden of capturing such insights on patients, site staff and study teams.

Dan Poppy

XMedidata uses cookies to enhance your experience, to display customized content in accordance with your browser settings, and to help us better understand how you use our website. By continuing to browse or closing this banner, you indicate your agreement. To learn more about the cookies we use and to set your own preferences, see our Privacy PolicySettingsAccept

Privacy & Cookies Policy

What are cookies?

We may collect information using “cookies.” Cookies are small data files stored on the hard drive of your computer or mobile device by a website. We may use both session cookies (which expire once you close your web browser) and persistent cookies (which stay on your computer or mobile device until you delete them) to provide you with a more personal and interactive experience on our Site.

We may collect information using “cookies.” Cookies are small data files stored on the hard drive of your computer or mobile device by a website. We may use both session cookies (which expire once you close your web browser) and persistent cookies (which stay on your computer or mobile device until you delete them) to provide you with a more personal and interactive experience on our Site.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

Analytical cookies allow us to analyze our Site. For example, we use analytical cookies to count the number of visitors and sources of web traffic so we can see how users move around our Site when they are using it. This helps us to improve the way our Site works, for example, by ensuring that users can find what they are looking for easily. All information these cookies collect is aggregated and therefore anonymized.

Cookies are used to deliver many types of targeted digital marketing. They store user data and behavior information, which allows advertising services to target audience groups according to variables including Age, Gender, Location, Interests, behavior on your website, search engines, and social media.